Myriad Genetics announced that the United Kingdom’s National Institute for Health and Care Excellence has included EndoPredict in its recommendations for guiding adjuvant chemotherapy decisions for people with ER-positive, HER2-negative early breast cancer and who are lymph node-negative. After an extensive technical review, NICE concluded that the clinical evidence justifies EndoPredict for patients with intermediate risk of distant recurrence as determined by a validated tool such as PREDICT or the Nottingham Prognostic Index. The information provided by the EndoPredict test will help patients choose, with their clinician, whether or not to pursue adjuvant chemotherapy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.